Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Wendy Readling

Physician Assistant Charlotte, NC Physician Assistant

NPI 1568711059 CMS profile 11235053

8401 University Exec Park Dr, Ste 128, Charlotte, NC 28262

Open in the dashboard

General payments

$4,071

131 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Wendy Readling of Charlotte, NC is reported in the CMS Open Payments database as having received $4,071 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $130 1
2023 General $434 5
2022 General $1,637 58
2021 General $1,870 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Readling
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Wendy Readling were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Wendy Readling Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,870 $132 $37–$438 $132
2022 $1,637 $155 $48–$522 $149
2023 $434 $167 $52–$557 $160
2024 $130 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AstraZeneca Pharmaceuticals LP $928 19 payments
  2. GlaxoSmithKline, LLC. $571 21 payments
  3. OptiNose US, Inc. $273 10 payments
  4. Genzyme Corporation $210 7 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $202 6 payments
  6. Regeneron Healthcare Solutions, Inc. $193 4 payments
  7. Amgen Inc. $188 9 payments
  8. Pfizer Inc. $173 10 payments
  9. kaleo, Inc. $165 8 payments
  10. Covis Pharma B.V. $155 10 payments
  11. Other $1,014 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,071 131 payments
Products named General payments · program years 2021–2024
  1. FASENRA $457 11 payments
  2. NUCALA $344 12 payments
  3. TEZSPIRE Respiratory $273 5 payments
  4. Xhance $273 10 payments
  5. DUPIXENT Immunology $229 8 payments
  6. DUPIXENT Inflammation And Immunology $193 4 payments
  7. AUVI-Q $165 8 payments
  8. ALVESCO $155 10 payments
  9. TEZSPIRE Inflammation $147 7 payments
  10. GIVLAARI $130 1 payment
  11. Other $1,608 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record